Empowering Oncology Decisions
DiagnoCure is a life sciences company commercializing high-value cancer diagnostic tests and lab services that increase clinician and patient confidence in making critical treatment decisions.
GCC Tests for Colorectal Cancer
DiagnoCure has acquired diagnostic rights to the GCC marker with utility in colorectal cancer and intends to launch the first GCC test in 2008.
Previstage™ GCC Colorectal Staging Test »
GCC colorectal cancer monitoring test »
PCA3 Molecular Marker
The PCA3 test for prostate cancer is now available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA™ PCA3 in vitro assay.
Special Media Coverage on PCA3 »
External site on PCA3, Ismar Healthcare »
Shc Proteins for Breast, Colon and
other Cancers
On August 2007, DiagnoCure acquired lead proprietary prognostic tests with applications in five tumor types, including breast and colon.
INVESTORS
|
1.89
-0.06
|
Open: 2.00
$CAN.
Quotes are delayed. |
- Corporate Fact Sheet (PDF)
- Corporate Brochure (PDF)
- 2007 Annual Report (PDF)
Latest News
May 1, 2008 - DiagnoCure to present at two conferences
April 1, 2008 - DiagnoCure provides update on operations
March 19, 2008 - New study supports use of PCA3-based test for prostate cancer diagnosis
Upcoming Events
May 30 - June 3, 2008
ASCO Annual '08 Meeting
Chicago, IL, USA
June 7 - 11, 2008
American Society of Colon & Rectal Surgeons Annual Meeting
Boston, MA, USA
September 25 - 28, 2008
College of American Pathologists Annual Meeting
San Diego, CA, USA